Active control trials: Endpoints beyond conventional efficacy and tolerability measures

Research output: Contribution to journalArticle

Abstract

Clinical trial endpoints often extend beyond conventional efficacy and tolerability measures. While it is generally assumed that seizure control without major adverse drug effects is by far the most important determinant of quality of life, other factors also are important. Pharmacokinetic endpoints could also provide relevant information for optimal drug use. Outcome measures could reveal drug effects on mood, headache, and sleep disorders, as well as overall quality of life and seizure severity.

Original languageEnglish
Pages (from-to)73-74
Number of pages2
JournalEpilepsy Research
Volume68
Issue number1
DOIs
Publication statusPublished - Jan 2006

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Neurology

Fingerprint Dive into the research topics of 'Active control trials: Endpoints beyond conventional efficacy and tolerability measures'. Together they form a unique fingerprint.

  • Cite this